Ampio Pharmaceuticals (AMPE) Insider Trading & Ownership $0.0021 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends Ampio Pharmaceuticals (NYSE:AMPE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.30%Number OfInsiders Buying(Last 3 Years)3Amount OfInsider Buying(Last 3 Years)$40,795.20Number OfInsiders Selling(Last 3 Years)0 Get AMPE Insider Trade Alerts Want to know when executives and insiders are buying or selling Ampio Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address AMPE Insider Buying and Selling by Quarter Ampio Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/8/2023J Kevin BuchiDirectorBuy1,250$6.00$7,500.00 5/24/2023Michael A MartinoCEOBuy3,844$5.80$22,295.20 5/11/2023David R StevensDirectorBuy2,500$4.40$11,000.00 (Data available from 1/1/2013 forward) AMPE Insider Trading Activity - Frequently Asked Questions Who is on Ampio Pharmaceuticals's Insider Roster? The list of insiders at Ampio Pharmaceuticals includes David R Stevens, J Kevin Buchi, and Michael A Martino. Learn more on insiders at AMPE. What percentage of Ampio Pharmaceuticals stock is owned by insiders? 3.30% of Ampio Pharmaceuticals stock is owned by insiders. Learn more on AMPE's insider holdings. Which Ampio Pharmaceuticals insiders have been buying company stock? The following insiders have purchased AMPE shares in the last 24 months: David R Stevens ($11,000.00), J Kevin Buchi ($7,500.00), and Michael A Martino ($22,295.20). How much insider buying is happening at Ampio Pharmaceuticals? Insiders have purchased a total of 7,594 AMPE shares in the last 24 months for a total of $40,795.20 bought. Ampio Pharmaceuticals Key ExecutivesMr. Michael A. Martino (Age 67)CEO & Director Compensation: $550kMr. Daniel G. Stokely CPA (Age 60)CFO, Corporate Secretary & Treasurer Compensation: $338.31kDr. David Bar-Or M.D. (Age 75)Founder & Chairman of Scientific Advisory Board Compensation: $145.6kApril RamirezClinical Trial Manager More Insider Trading Tools from MarketBeat Related Companies Vaxxinity Insider Trading Evelo Biosciences Insider Trading Comera Life Sciences Insider Trading Genocea Biosciences Insider Trading Calithera Biosciences Insider Trading Clever Leaves Insider Trading eFFECTOR Therapeutics Insider Trading biote Insider Trading Clever Leaves Insider Trading Fortress Biotech Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NYSE:AMPE) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
